Trex1 Knockout Mouse

Constitutive Knock Out

Trex1 Constitutive Knock Out Mouse Model
This line is cryopreserved and requires cryorecovery.

B6;129 Background

  • Model #
  • Genotype
  • Nomenclature
  • 13076-F
  • 13076-M
  • Constitutive knockout of the three prime repair exonuclease I gene (Trex1)
  • Model of Aicardi-Goutieres syndrome
  • Displays inflammatory myocarditis and autoimmune disease
  • Homozygous knockouts have a reduced lifespan


The Trex1 Knockout Mouse was developed in the laboratories of Tomas Lindahl at the Clare Hall Laboratories, Imperial Cancer Research Fund (now Cancer Research UK). The model was created using a targeting vector that replaced amino acids 103-207 of the Trex1 open reading frame with a neo cassette in GK129 ES cells derived from the 129P2 strain. Targeted ES cells were injected into C57BL/6J blastocysts. Taconic received frozen embryos from CRT in 2013.


Cancer Research Technology



Initial Publication:

Morita M, Stamp G, Robins P, Dulic A, Rosewell I, Hrivnak G, Daly G, Lindahl T, Barnes DE. (2004) Gene-targeted mice lacking the Trex1 (DNase III) 3'-->5' DNA exonuclease develop inflammatory myocarditis. Mol Cell Biol. 24(15):6719-27.

Access to this model requires execution of a Limited Breeding Agreement. Current Limited Breeding Agreement fees for this model are $2,500/year (€2000/year) for nonprofit users and $10,000/year (€8000) for for-profit users.

Purchase of line #13073 includes the right under the patents owned by Le Centre Européen de Recherche en Biologie et en Médecine ("CERBM") to perform inducible deletion (e.g. tamoxifen induction based deletion) using the CreER gene.